Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) EBITDA: 2019-2025

Historic EBITDA for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to -$43.5 million.

  • Legend Biotech's EBITDA rose 31.48% to -$43.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.2 million, marking a year-over-year increase of 79.17%. This contributed to the annual value of -$2.5 million for FY2024, which is 98.95% up from last year.
  • Legend Biotech's EBITDA amounted to -$43.5 million in Q3 2025, which was up 66.58% from -$130.0 million recorded in Q2 2025.
  • Legend Biotech's EBITDA's 5-year high stood at $60.7 million during Q1 2025, with a 5-year trough of -$206.1 million in Q2 2023.
  • Moreover, its 3-year median value for EBITDA was -$82.4 million (2023), whereas its average is -$73.3 million.
  • Within the past 5 years, the most significant YoY rise in Legend Biotech's EBITDA was 156.34% (2025), while the steepest drop was 352.54% (2025).
  • Over the past 5 years, Legend Biotech's EBITDA (Quarterly) stood at -$88.9 million in 2021, then tumbled by 58.07% to -$140.6 million in 2022, then dropped by 4.43% to -$146.8 million in 2023, then spiked by 127.59% to $40.5 million in 2024, then surged by 31.48% to -$43.5 million in 2025.
  • Its EBITDA stands at -$43.5 million for Q3 2025, versus -$130.0 million for Q2 2025 and $60.7 million for Q1 2025.